Arcellx (NASDAQ:ACLX – Get Rating) and Freeline Therapeutics (NASDAQ:FRLN – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.
Insider and Institutional Ownership
92.3% of Arcellx shares are held by institutional investors. Comparatively, 58.5% of Freeline Therapeutics shares are held by institutional investors. 1.9% of Freeline Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Get Arcellx alerts:Analyst Ratings
This is a breakdown of current ratings and target prices for Arcellx and Freeline Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arcellx | 0 | 0 | 8 | 0 | 3.00 |
| Freeline Therapeutics | 0 | 1 | 4 | 0 | 2.80 |
Profitability
This table compares Arcellx and Freeline Therapeutics' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arcellx | N/A | -68.99% | -42.26% |
| Freeline Therapeutics | N/A | -101.38% | -67.17% |
Valuation & Earnings
This table compares Arcellx and Freeline Therapeutics' revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Arcellx | N/A | N/A | -$64.97 million | ($44.41) | -0.72 |
| Freeline Therapeutics | N/A | N/A | -$140.39 million | ($2.12) | -0.27 |
Arcellx is trading at a lower price-to-earnings ratio than Freeline Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Arcellx beats Freeline Therapeutics on 6 of the 10 factors compared between the two stocks.
About Arcellx
(Get Rating)
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
About Freeline Therapeutics
(Get Rating)
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.